
|Videos|July 11, 2023
PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future
The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.
Advertisement
Episodes in this series

Advertisement
Related to this article

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Testosterone Screening and Cardiovascular Safety in TRAVERSE
2
LIB-01 enters phase 2b development for erectile dysfunction
3
Prostate Cancer, BPH, and Testosterone Scheduling Myths
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5




